Status:
COMPLETED
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
Forest Laboratories
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-90 years
Phase:
PHASE4
Brief Summary
Recent data show that marked cell damage precedes the clinical manifestation of Alzheimer's disease (AD). Hence, targeting populations at risk with pharmacological interventions is a possible strategy...
Eligibility Criteria
Inclusion
- presence of subjective memory complaints without objective evidence of impaired cognition
- family history of Alzheimer's disease
Exclusion
- major depression
- Parkinson's disease
- stroke
- seizures
- uncontrolled diabetes or hypertension
- current benzodiazepine use
- substance abuse
- contraindication for MRI
- contraindications for memantine
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00933608
Start Date
July 1 2009
End Date
September 1 2011
Last Update
October 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU School of Medicine, Dept. of Psychiatry, Center for Brain Health
New York, New York, United States, 10016